Galectin Therapeutics Inc (GALT) Company Profile & Statistics

Galectin Therapeutics Inc
GALT
(Nasdaq - US)
Closed
2.94
+0.05 (+1.73%)
in:usd•As of: Nov 12, 2024 15:59 UTC -5
Open
3.02
High
3.02
Low
2.93

About Galectin Therapeutics Inc

CEO

Joel Lewis

Headquarters

4960 peachtree industrial blvd., suite 240

norcross, ga 30071, united states

Auditor

Cherry Bekaert LLP

Employees

Share Holders

138

Website

www.galectintherapeutics.com

Industry

biotechnology

Sector

health technology

Company Overview

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Galectin Therapeutics, formerly known as Pro-Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts.

Galectin Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	183.10M
Enterprise Value	250.93M
Enterprise Value/EBITDA (ttm)	-6.33
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	N/A
Price to Sales (ttm)	N/A
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	0.00%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	0.00%
Return on Equity (ttm)	N/A
Return on Invested Capital (ttm)	-399.21%
Return on Assets (ttm)	-184.63%

Income Statement

Revenue (ttm)	0.00
Revenue Per Share (ttm)	0.00
Gross Profit (ttm)	0.00
EBITDA (ttm)³	-39.63M
Net Income Avi to Common (ttm)	-48.03M
Diluted EPS (ttm)	-0.79

Share Statistics

Beta (5Y Monthly)	0.62
52-Week Change	50.77%
S&P500 52-Week Change	35.64%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	62.28M
Dividend Yield	0.00%
Float ⁴	29.46M
% Held by Insiders	52.70%
% Held by Institutions	11.68%

Balance Sheet

Total Cash (mrq)	25.60M
Total Cash Per Share (mrq)	0.41
Total Debt (mrq)	93.42M
Total Debt/Equity (mrq)	-113.72%
Current Ratio (mrq)	1.87%
Quick Ratio (mrq)	1.87%
Book Value Per Share (mrq)	-1.32

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.33
Free Cash Flow (ytd)	-20.44M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Galectin Therapeutics Inc

Trade With A Regulated Broker